247 filings
Page 2 of 13
8-K
rkwspg6 n4
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
vjtaqx7
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
p3hv28ocfn8h5a9awp2w
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
ftcvn
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
6khf cwxm9apeeis2
9 May 22
Submission of Matters to a Vote of Security Holders
5:03pm
8-K
0p7d06zf ni
6 May 22
Other Events
4:37pm
8-K
a7gno3
11 Apr 22
Other Events
3:13pm
8-K
ksi 38zk7imh9pmp
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm
8-K
5u2n bdlim17
3 Nov 21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
4:11pm
8-K
rvi2hs8872
23 Aug 21
Other Events
4:43pm
8-K
b13fh
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
8-K
8bdsr5ipxw 62sy3t
3 Aug 21
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
9:17am
8-K
xht7vmzixh
2 Aug 21
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
9:22am
8-K
mttl2t3z
21 Jul 21
Lumos Pharma Announces Clinical Updates
8:33am
8-K
4bd6xbx
28 Jun 21
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
8:11am
8-K
5kf6at6mzkn93g7qv29x
21 May 21
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
4q3ojv
5 May 21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:28pm
8-K
6nc128h6l4c7hh3jd
29 Apr 21
Other Events
4:48pm
8-K
f91etiynm rujeie04
27 Apr 21
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
8:12am
8-K
d2y9ji9dq2tiovk 8k3
21 Apr 21
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
4:36pm